Hydroxychloroquine and azithromycin as potential treatments for COVID-19; clinical status impacts the outcome

• Published in: Journal of pharmacokinetics and pharmacodynamics Vol. 47; no. 3; pp. 187 - 188
• Main Authors: Okour, Malek, Al-Kofahi, Mahmoud, Austin, Daren
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.06.2020; Springer Nature B.V
• Subjects: Antibiotics; Azithromycin; Azithromycin - therapeutic use; Betacoronavirus - drug effects; Biochemistry; Biomedical and Life Sciences; Biomedical Engineering and Bioengineering; Biomedicine; Clinical Trials as Topic; Commentary; Coronavirus Infections - diagnosis; Coronavirus Infections - drug therapy; Coronavirus Infections - physiopathology; Coronavirus Infections - virology; COVID-19; Drug Therapy, Combination; Humans; Hydroxychloroquine; Hydroxychloroquine - blood; Hydroxychloroquine - pharmacokinetics; Hydroxychloroquine - therapeutic use; Immunomodulators; Models, Biological; Pandemics; Pharmacology/Toxicology; Pharmacy; Pneumonia, Viral - diagnosis; Pneumonia, Viral - drug therapy; Pneumonia, Viral - physiopathology; Pneumonia, Viral - virology; SARS-CoV-2; Treatment Outcome; Veterinary Medicine/Veterinary Science; Viral Load - drug effects